Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Al-Sawaf O, et al.
Journal of Clinical Oncology
November 2021
Authors and Affiliates
Othman Al-Sawaf, MD1,2,3; Can Zhang, PhD1; Tong Lu, PhD4; Michael Z. Liao, PhD4; Anesh Panchal, MSc5; Sandra Robrecht, PhD1; Travers Ching, PhD6; Maneesh Tandon, MBChB5; Anna-Maria Fink, MD1; Eugen Tausch, MD7; Christof Schneider, MD7;
Matthias Ritgen, MD8; Sebastian Bottcher, MD ¨ 9; Karl-Anton Kreuzer, MD1; Brenda Chyla, PhD10; Dale Miles, PhD4; Clemens-Martin Wendtner, MD11; Barbara Eichhorst, MD1; Stephan Stilgenbauer, MD7,12; Yanwen Jiang, PhD4; Michael Hallek, MD1; and Kirsten Fischer, MD1
1University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Germany 2The Francis Crick Institute, London, United Kingdom 3UCL Cancer Institute, University College London, London, United Kingdom 4Genentech, San Francisco, CA 5Roche Products Ltd, Welwyn Garden City, United Kingdom 6Adaptive Biotechnologies Corp, Seattle, WA 7
Department of Internal Medicine III, Ulm University, Ulm, Germany 8Department II of Internal Medicine, University of Schleswig- Holstein, Kiel, Germany 9Clinic III, Special Hematology Laboratory, Rostock University Medical School, Rostock, Germany 10AbbVie Inc, Chicago, IL 11Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany 12Department of Internal Medicine I, Saarland University Medical Center, Homburg, Germany